{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:44:44Z","timestamp":1791841484745,"version":"4.3.4"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017638","name":"Ministry of Health of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013833","name":"Sechenov University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.isci.2026.115812","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:17:18Z","timestamp":1776727038000},"page":"115812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncolytic myxoma virus and engineering strategies for advanced cancer immunotherapy"],"prefix":"10.1016","volume":"29","author":[{"given":"A.D.","family":"Trujillo Yeriomenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Isaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"Idota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Zhivoderov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Yurkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-1780","authenticated-orcid":false,"given":"A.S.","family":"Malogolovkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115812_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2026.115812_bib2","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.vaccine.2013.05.056","article-title":"Oncolytic myxoma virus: the path to clinic","volume":"31","author":"Chan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.isci.2026.115812_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/jcm9010171","article-title":"Oncolytic virotherapy with myxoma virus","volume":"9","author":"Rahman","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.isci.2026.115812_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1540397","article-title":"Shaping viral immunotherapy towards cancer-targeted immunological cell death","volume":"15","author":"Isaeva","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/v13071271","article-title":"Combinatorial approaches for cancer treatment using oncolytic viruses: Projecting the perspectives through clinical trials outcomes","volume":"13","author":"Malogolovkin","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.isci.2026.115812_bib9","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2026.115812_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jjco\/hyy170","article-title":"Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives","volume":"49","author":"Taguchi","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene Firadenovec: First Approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2026.115812_bib13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/viro.1999.0001","article-title":"The complete DNA sequence of myxoma virus","volume":"264","author":"Cameron","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/v7031020","article-title":"Myxoma virus and the Leporipoxviruses: An evolutionary paradigm","volume":"7","author":"Kerr","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/smim.2000.0298","article-title":"Immunomodulatory proteins of myxoma virus","volume":"13","author":"Barrett","year":"2001","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.micinf.2010.08.012","article-title":"The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics","volume":"12","author":"Liu","year":"2010","journal-title":"Microb. Infect."},{"key":"10.1016\/j.isci.2026.115812_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/08828240260066198","article-title":"Immune responses to myxoma virus","volume":"15","author":"Kerr","year":"2002","journal-title":"Viral Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/13550280701591526","article-title":"Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells","volume":"13","author":"Barrett","year":"2007","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.isci.2026.115812_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1128\/JVI.01408-06","article-title":"Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells","volume":"81","author":"Stanford","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-09-1510","article-title":"Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin","volume":"70","author":"Lun","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115812_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrmicro1099","article-title":"Poxvirus tropism","volume":"3","author":"McFadden","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.isci.2026.115812_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cytogfr.2010.02.010","article-title":"Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus","volume":"21","author":"Rahman","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.isci.2026.115812_bib23","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus","volume":"18","author":"Bartee","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2026.115812_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-virology-031413-085442","article-title":"Oncolytic poxviruses","volume":"1","author":"Chan","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-065X.1999.tb01286.x","article-title":"Immunomodulation by viruses: the myxoma virus story","volume":"168","author":"Nash","year":"1999","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.115812_bib26","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00705-006-0791-2","article-title":"Ultrastructural study of myxoma virus morphogenesis","volume":"151","author":"Duteyrat","year":"2006","journal-title":"Arch. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2164-12-261","article-title":"Genes in the terminal regions of orthopoxvirus genomes experience adaptive molecular evolution","volume":"12","author":"Esteban","year":"2011","journal-title":"BMC Genom."},{"key":"10.1016\/j.isci.2026.115812_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/viro.1997.8894","article-title":"The Myxoma Virus M-T4 Gene Encodes a Novel RDEL-Containing Protein That Is Retained within the Endoplasmic Reticulum and Is Important for the Productive Infection of Lymphocytes","volume":"239","author":"Barry","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1006\/viro.1999.9946","article-title":"Role of the C-Terminal RDEL Motif of the Myxoma Virus M-T4 Protein in Terms of Apoptosis Regulation and Viral Pathogenesis","volume":"263","author":"Hnatiuk","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib34","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1128\/JVI.79.16.10750-10763.2005","article-title":"Myxoma Virus M-T5 Protects Infected Cells from the Stress of Cell Cycle Arrest through Its Interaction with Host Cell Cullin-1","volume":"79","author":"Johnston","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib35","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/JVI.80.3.1140-1151.2006","article-title":"Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria","volume":"80","author":"Su","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003465","article-title":"Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA\/DHX9 to promote expanded host tropism and viral replication","volume":"9","author":"Rahman","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.115812_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/JVI.79.1.597-601.2005","article-title":"The Poxviral RING Protein p28 Is a Ubiquitin Ligase That Targets Ubiquitin to Viral Replication Factories","volume":"79","author":"Nerenberg","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/viro.1998.9304","article-title":"Shope Fibroma Virus RING Finger Protein N1R Binds DNA and Inhibits Apoptosis","volume":"249","author":"Brick","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib39","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1128\/JVI.78.5.2510-2516.2004","article-title":"A Virulence Factor of Myxoma Virus Colocalizes with NF-\u03baB in the Nucleus and Interferes with Inflammation","volume":"78","author":"Camus-Bouclainville","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib40","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0022-2836(02)00858-6","article-title":"Myxoma virus immunomodulatory protein M156R is a structural mimic of eukaryotic translation initiation factor eIF2alpha","volume":"322","author":"Ramelot","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.isci.2026.115812_bib41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","article-title":"eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death","volume":"25","author":"Bezu","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.isci.2026.115812_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semcancer.2015.02.004","article-title":"eIF2\u03b1 phosphorylation as a biomarker of immunogenic cell death","volume":"33","author":"Kepp","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.isci.2026.115812_bib43","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1021\/bi00227a020","article-title":"Synthesis and structure-activity study of myxoma virus growth factor","volume":"30","author":"Lin","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.isci.2026.115812_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virol.2005.03.037","article-title":"Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo","volume":"337","author":"Cameron","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1051\/vetres:2006054","article-title":"Myxoma virus in the European rabbit: interactions between the virus and its susceptible host","volume":"38","author":"Stanford","year":"2007","journal-title":"Vet. Res."},{"key":"10.1016\/j.isci.2026.115812_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/JVI.01633-06","article-title":"M135R is a novel cell surface virulence factor of myxoma virus","volume":"81","author":"Barrett","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib47","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1128\/JVI.79.10.6052-6067.2005","article-title":"Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo","volume":"79","author":"Cameron","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib48","doi-asserted-by":"crossref","first-page":"9602","DOI":"10.1128\/JVI.01078-09","article-title":"Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200)","volume":"83","author":"Zhang","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01570-16","article-title":"Genetic Variability of Myxoma Virus Genomes","volume":"91","author":"Braun","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1297-9716-42-76","article-title":"The current status and future directions of myxoma virus, a master in immune evasion","volume":"42","author":"Spiesschaert","year":"2011","journal-title":"Vet. Res."},{"key":"10.1016\/j.isci.2026.115812_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/v7020709","article-title":"Poxviral Ankyrin Proteins","volume":"7","author":"Herbert","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1051\/vetres:2008049","article-title":"M148R and M149R are two virulence factors for myxoma virus pathogenesis in the European rabbit","volume":"40","author":"Blani\u00e9","year":"2009","journal-title":"Vet. Res."},{"key":"10.1016\/j.isci.2026.115812_bib53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/v11060530","article-title":"Genetic Characterization of a Recombinant Myxoma Virus in the Iberian Hare (Lepus granatensis)","volume":"11","author":"\u00c1gueda-Pinto","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib54","first-page":"273","article-title":"Lessons in d\u00e9tente or know thy host: the immunomodulatory gene products of myxoma virus","volume":"28","author":"Z\u00fa\u00f1iga","year":"2003","journal-title":"J. Bio. Sci."},{"key":"10.1016\/j.isci.2026.115812_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jb\/mvj160","article-title":"A Novel Family of Membrane-Bound E3 Ubiquitin Ligases","volume":"140","author":"Ohmura-Hoshino","year":"2006","journal-title":"J. Biochem."},{"key":"10.1016\/j.isci.2026.115812_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066825","article-title":"Myxoma Virus Infection Promotes NK Lysis of Malignant Gliomas In Vitro and In Vivo","volume":"8","author":"Ogbomo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.115812_bib57","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1128\/JVI.77.2.1427-1440.2003","article-title":"The PHD\/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4","volume":"77","author":"Mansouri","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1008136431036","article-title":"Myxoma virus expresses a TNF receptor homolog with two distinct functions","volume":"21","author":"Xu","year":"2000","journal-title":"Virus Genes"},{"key":"10.1016\/j.isci.2026.115812_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010316","article-title":"Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes\/macrophages","volume":"18","author":"Conrad","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.115812_bib60","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JVI.02243-10","article-title":"M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells","volume":"85","author":"Liu","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.virol.2006.11.015","article-title":"Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells","volume":"361","author":"Barrett","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib62","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.virusres.2009.05.009","article-title":"Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits","volume":"144","author":"Barrett","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.isci.2026.115812_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-immunol-090222-110227","article-title":"Poxvirus immune evasion","volume":"42","author":"Hernaez","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/v9080215","article-title":"Poxviruses Utilize Multiple Strategies to Inhibit Apoptosis","volume":"9","author":"Nichols","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib30","first-page":"105","article-title":"Subversion of Programed Cell Death by Poxviruses","volume":"442","author":"Koehler","year":"2023","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10010006","article-title":"Poxviral Strategies to Overcome Host Cell Apoptosis","volume":"10","author":"Suraweera","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.isci.2026.115812_bib63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omto.2017.08.002","article-title":"Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model","volume":"6","author":"Nounamo","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2016.12.002","article-title":"Ex vivo oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft versus tumor","volume":"4","author":"Lilly","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.omto.2020.07.003","article-title":"Myxoma virus-loaded mesenchymal stem cells in experimental oncolytic therapy of Murine pulmonary melanoma","volume":"18","author":"Jazowiecka-Rakus","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/OV.S220420","article-title":"Impact of induced syncytia formation on the oncolytic potential of myxoma virus","volume":"8","author":"Burton","year":"2019","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib67","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI121323","article-title":"Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival","volume":"129","author":"Kellish","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115812_bib68","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.28205","article-title":"Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk\u2217MYC mouse myeloma","volume":"13","author":"Villa","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.115812_bib69","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/neuonc\/now006","article-title":"M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma","volume":"18","author":"Pisklakova","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/OV.S252727","article-title":"Treatment of an alveolar rhabdomyosarcoma allograft with recombinant myxoma virus and oclacitinib","volume":"9","author":"Ashton","year":"2020","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib71","first-page":"1","article-title":"Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma","volume":"2","author":"Doty","year":"2013","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109801","article-title":"Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity","volume":"9","author":"Tosic","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.115812_bib73","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-18-3626","article-title":"Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115812_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004770","article-title":"TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy","volume":"10","author":"Valenzuela-Cardenas","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115812_bib75","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.omto.2023.08.014","article-title":"Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection","volume":"30","author":"Thomas","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194703","article-title":"Dual-armed oncolytic myxoma virus encoding IFN-\u03b3 and CD47 promotes lymphocyte infiltration and tumor suppression of syngeneic Murine melanoma","volume":"15","author":"Woo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.115812_bib77","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/cancers13061394","article-title":"Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for Murine pancreatic adenocarcinoma","volume":"13","author":"Jazowiecka-Rakus","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.115812_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082022","article-title":"Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma","volume":"14","author":"Jazowiecka-Rakus","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.115812_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020337","article-title":"Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma","volume":"14","author":"Christie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.115812_bib80","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41417-021-00351-3","article-title":"Cutting both ways: the innate immune response to oncolytic virotherapy","volume":"29","author":"Mealiea","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.isci.2026.115812_bib81","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2026.115812_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.isci.2026.115812_bib83","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.isci.2026.115812_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102054","article-title":"Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities","volume":"88","author":"de Vries","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.isci.2026.115812_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5430\/jst.v4n2p25","article-title":"Systemic therapy for bladder cancer - a medical oncologist\u2019s perspective","volume":"4","author":"Teply","year":"2014","journal-title":"J. Solid Tumors"},{"key":"10.1016\/j.isci.2026.115812_bib86","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/annonc\/mdu442","article-title":"Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach","volume":"25","author":"Rotolo","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib87","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ijrobp.2020.11.052","article-title":"Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile","volume":"109","author":"Federico","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.isci.2026.115812_bib88","article-title":"Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition","volume":"6","author":"Huang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.115812_bib89","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-08-0037","article-title":"Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination","volume":"14","author":"Tseng","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115812_bib90","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.3390\/ijms23137207","article-title":"Glioblastoma treatment: State-of-the-art and future perspectives","volume":"23","author":"Rodr\u00edguez-Camacho","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.115812_bib91","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma multiforme-A literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib92","doi-asserted-by":"crossref","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","article-title":"Barriers and opportunities for gemcitabine in pancreatic cancer therapy","volume":"324","author":"Beutel","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.isci.2026.115812_bib93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/ijms22010029","article-title":"Extracellular matrix composition modulates the responsiveness of differentiated and stem pancreatic cancer cells to lipophilic derivate of gemcitabine","volume":"22","author":"Forciniti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.115812_bib94","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/mt.2011.293","article-title":"Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer","volume":"20","author":"Wennier","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115812_bib95","series-title":"StatPearls [Internet]","article-title":"Cyclophosphamide","author":"Ogino","year":"2023"},{"key":"10.1016\/j.isci.2026.115812_bib96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-018-0703-z","article-title":"Principles of adoptive T cell therapy in cancer","volume":"41","author":"Met","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.isci.2026.115812_bib97","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-011-1045-z","article-title":"Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors","volume":"60","author":"Thomas","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.115812_bib98","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.omto.2021.07.014","article-title":"Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma","volume":"22","author":"Christie","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1476-4598-13-82","article-title":"Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo","volume":"13","author":"Weng","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.115812_bib100","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1158\/0008-5472.CAN-07-1214","article-title":"Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin","volume":"67","author":"Lun","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115812_bib101","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/pharmaceutics13091522","article-title":"Selinexor and the selective inhibition of nuclear export: A new perspective on the treatment of sarcomas and other solid and non-solid tumors","volume":"13","author":"Marretta","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2026.115812_bib102","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/2767-9764.CRC-22-0483","article-title":"Nuclear export inhibitor selinexor enhances oncolytic myxoma virus therapy against cancer","volume":"3","author":"Rahman","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.isci.2026.115812_bib103","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00262-014-1561-8","article-title":"Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells","volume":"63","author":"Kosaka","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.115812_bib104","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/ijc.28607","article-title":"Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors","volume":"134","author":"Eberst\u00e5l","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2026.115812_bib105","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2026.115812_bib106","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL(\u00ae)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J. Vet. Pharmacol. Therapeut."},{"key":"10.1016\/j.isci.2026.115812_bib107","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4939-9794-7_6","article-title":"Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer","volume":"2058","author":"Villa","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.isci.2026.115812_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib109","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib110","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jcyt.2015.09.005","article-title":"Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells","volume":"17","author":"Bonomi","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib111","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13267","article-title":"Immunogenicity of mesenchymal stromal\/stem cells","volume":"97","author":"Chen","year":"2023","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omto.2020.06.011","article-title":"Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma","volume":"18","author":"Villa","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib113","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2014-07-587329","article-title":"Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells","volume":"125","author":"Villa","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115812_bib114","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115812_bib115","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1038\/onc.2010.137","article-title":"The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status","volume":"29","author":"Kim","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.115812_bib116","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1743-422X-8-481","article-title":"Herpes simplex virus infects most cell types in vitro: clues to its success","volume":"8","author":"Karasneh","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.isci.2026.115812_bib117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib118","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.virusres.2009.02.010","article-title":"Adenovirus receptors and their implications in gene delivery","volume":"143","author":"Sharma","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.isci.2026.115812_bib119","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423171","article-title":"Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages","volume":"7","author":"Masemann","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.isci.2026.115812_bib121","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1134\/S0026893312060064","article-title":"Oncolytic viruses in the therapy of gliomas","volume":"46","author":"Gubanova","year":"2012","journal-title":"Mol. Biol."},{"key":"10.1016\/j.isci.2026.115812_bib122","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.omto.2021.03.013","article-title":"Efficient delivery of oncolytic enterovirus by carrier cell line NK-92","volume":"21","author":"Podshivalova","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib123","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1134\/S1019331619020023","article-title":"Could Oncolytic Viruses Provide a Breakthrough in Oncology? Her","volume":"89","author":"Chumakov","year":"2019","journal-title":"Russ. Acad. Sci."},{"key":"10.1016\/j.isci.2026.115812_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195425","article-title":"Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model","volume":"13","author":"Yurchenko","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.115812_bib125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0145-305X(99)00077-4","article-title":"The avian response to Newcastle disease virus","volume":"24","author":"Seal","year":"2000","journal-title":"Dev. Comp. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib126","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/JVI.01612-07","article-title":"NPXY motifs in the \u03b21 integrin cytoplasmic tail are required for functional Reovirus entry","volume":"82","author":"Maginnis","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib127","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/JVI.80.3.1261-1270.2006","article-title":"JAM-A-independent, antibody-mediated uptake of reovirus into cells leads to apoptosis","volume":"80","author":"Danthi","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.115812_bib129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OV.S143808","article-title":"Current understanding of reovirus oncolysis mechanisms","volume":"7","author":"Phillips","year":"2018","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/v8040112","article-title":"Measles virus fusion protein: Structure, function and inhibition","volume":"8","author":"Plattet","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib131","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1126\/science.aaa5137","article-title":"Structural virology. Near-atomic cryo-EM structure of the helical measles virus nucleocapsid","volume":"348","author":"Gutsche","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.115812_bib132","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/35022579","article-title":"SLAM (CDw150) is a cellular receptor for measles virus","volume":"406","author":"Tatsuo","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115812_bib133","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OV.S218494","article-title":"Virus-receptor interactions: Structural insights for oncolytic virus development","volume":"8","author":"Jayawardena","year":"2019","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib134","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcdb.2016.07.015","article-title":"Membrane fusion during poxvirus entry","volume":"60","author":"Moss","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2026.115812_bib135","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/jgv.0.000980","article-title":"Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update","volume":"98","author":"Felt","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib136","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fvl.09.72","article-title":"Internalization and fusion mechanism of vesicular stomatitis virus and related rhabdoviruses","volume":"5","author":"Sun","year":"2010","journal-title":"Future Virol."},{"key":"10.1016\/j.isci.2026.115812_bib137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virol.2005.05.006","article-title":"Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells","volume":"338","author":"Sun","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib138","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11912-018-0749-z","article-title":"Correction to: The role of oncolytic viruses in the treatment of melanoma","volume":"20","author":"Bayan","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.isci.2026.115812_bib139","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/gt.2008.72","article-title":"Gene therapy progress and prospects cancer: oncolytic viruses","volume":"15","author":"Liu","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.isci.2026.115812_bib140","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/cncr.28862","article-title":"Oncolytic polio virotherapy of cancer","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.115812_bib141","first-page":"207","article-title":"Oncolytic virotherapy using herpes simplex virus: how far have we come?","volume":"4","author":"Sokolowski","year":"2015","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.isci.2026.115812_bib142","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2010.02.027","article-title":"Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells","volume":"401","author":"Villa","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib143","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jviromet.2014.11.009","article-title":"Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR\/Cas9 nucleases","volume":"213","author":"Russell","year":"2015","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.isci.2026.115812_bib144","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3142306","article-title":"Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective","volume":"2022","author":"Garmaroudi","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.isci.2026.115812_bib145","article-title":"Herpes Simplex Virus Cell Entry Mechanisms: An Update","volume":"10","author":"Madavaraju","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.isci.2026.115812_bib146","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118246","article-title":"Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option","volume":"14","author":"Asija","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib148","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omto.2018.09.001","article-title":"Oncolytic virus-mediated RAS targeting in rhabdomyosarcoma","volume":"11","author":"Phelps","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115812_bib149","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/14712598.7.9.1415","article-title":"Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer","volume":"7","author":"Stanford","year":"2007","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.isci.2026.115812_bib150","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1158\/0008-5472.CAN-05-1201","article-title":"Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas","volume":"65","author":"Lun","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115812_bib151","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/S1152851703000577","article-title":"Poliovirus receptor CD155-targeted oncolysis of glioma","volume":"6","author":"Merrill","year":"2004","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.isci.2026.115812_bib152","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41586-020-2369-7","article-title":"IGF1R is an entry receptor for respiratory syncytial virus","volume":"583","author":"Griffiths","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115812_bib153","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1073\/pnas.0832269100","article-title":"Visualizing infection of individual influenza viruses","volume":"100","author":"Lakadamyali","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115812_bib154","doi-asserted-by":"crossref","DOI":"10.3390\/v9080207","article-title":"The Susceptibilities of Respiratory Syncytial Virus to Nucleolin Receptor Blocking and Antibody Neutralization are Dependent upon the Method of Virus Purification","volume":"9","author":"Bilawchuk","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105336","article-title":"Contribution of Syndecans to the Cellular Entry of SARS-CoV-2","volume":"22","author":"Hud\u00e1k","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.115812_bib156","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/CMR.00027-09","article-title":"Modern uses of electron microscopy for detection of viruses","volume":"22","author":"Goldsmith","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.isci.2026.115812_bib157","article-title":"Cryo-EM structure of the vaccinia virus entry fusion complex reveals a multicomponent fusion machinery","volume":"12","author":"Lin","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.isci.2026.115812_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27185898","article-title":"Kinetic and Structural Aspects of Glycosaminoglycan-Monkeypox Virus Protein A29 Interactions Using Surface Plasmon Resonance","volume":"27","author":"Shi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.isci.2026.115812_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/v15071432","article-title":"Applications of the Microscale Thermophoresis Binding Assay in COVID-19 Research","volume":"15","author":"Nydegger","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.115812_bib160","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4049\/jimmunol.148.3.881","article-title":"Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus","volume":"148","author":"Boshkov","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.115812_bib161","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/viro.1999.9840","article-title":"Endosomal\/lysosomal retention and degradation of major histocompatibility complex class I molecules is induced by myxoma virus","volume":"261","author":"Z\u00fa\u00f1iga","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.isci.2026.115812_bib166","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11262-024-02090-7","article-title":"Comparative analysis of two novel complete genomes of myxoma virus vaccine strains","volume":"60","author":"Volodina","year":"2024","journal-title":"Virus Genes"},{"key":"10.1016\/j.isci.2026.115812_bib167","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/JVI.02189-08","article-title":"Genome comparison of a nonpathogenic myxoma virus field strain with its ancestor, the virulent Lausanne strain","volume":"83","author":"Morales","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.115812_bib168","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000150339","article-title":"New developments in the virus therapy of cancer: a historical review","volume":"36","author":"Sinkovics","year":"1993","journal-title":"Intervirology"},{"key":"10.1016\/j.isci.2026.115812_bib172","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115812_bib173","article-title":"The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapy","author":"O\u2019Melia","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2026.115812_bib174","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/cancers17142296","article-title":"Cell carriers for oncolytic virus delivery: Prospects for systemic administration","volume":"17","author":"Sarkisova","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.115812_bib175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1389201043376670","article-title":"SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy","volume":"5","author":"Kimchi-Sarfaty","year":"2004","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226011879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226011879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:47:35Z","timestamp":1791838055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226011879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589004226011879"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115812","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic myxoma virus and engineering strategies for advanced cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115812"}}